BET inhibitor resistance emerges from leukaemia stem cells

Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks(1,2). Early clinical trials have shown promise, especially in acute myeloid leukaem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Fong, Chun Yew, Gilan, Omer, Lam, Enid Y. N., Rubin, Alan F., Ftouni, Sarah, Tyler, Dean, Stanley, Kym, Sinha, Devbarna, Yeh, Paul, Morison, Jessica, Giotopoulos, George, Lugo, Dave, Jeffrey, Philip, Lee, Stanley Chun-Wei, Carpenter, Christopher, Gregory, Richard, Ramsay, Robert G., Lane, Steven W., Abdel-Wahab, Omar, Kouzarides, Tony, Johnstone, Ricky W., Dawson, Sarah-Jane, Huntly, Brian J. P., Prinjha, Rab K., Papenfuss, Anthony T., Dawson, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069604/
https://ncbi.nlm.nih.gov/pubmed/26367796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14888
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados